argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases.
Join argenx as a Senior Translational Scientist to drive clinical readiness through early translational strategies. The selected candidate will implement and perform translational studies to unravel the mode of action of key assets and support indication selection. The position is based at our facility in Zwijnaarde, Belgium, with an expected on-site presence of 3 days per week.
argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases.
argenx